Furoscix Injection
NDC Package 71767-111-01

11-digit billing NDC: 71767011101 · Billing unit: ML · 1 ML per package
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Furoscix (furosemide) injection is furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This formulation utilizes a injection delivery system. Marketed by Scpharmaceuticals Inc., A Wholly Owned Subsidiary Of Mannkind Corporation, this product is identified by NDC 71767-111 and is authorized under FDA application NDA209988.

Identification & Billing

NDC Package Code
71767-111-01
Package Description
1 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS
Product Code
71767-111
11-Digit Billing Format
71767011101
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
1 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Furoscix
Non-Proprietary Name
Furosemide
Substance Name
Furosemide
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
FUROSEMIDE 80 mg/mL
Pharmacologic Class
Usage Information
Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Regulatory & Marketing

Labeler Name
Scpharmaceuticals Inc., A Wholly Owned Subsidiary Of Mannkind Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA209988
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-27-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J1947
Source: PDAC
INJECTION, FUROSEMIDE (FUROSCIX), 1 MG
HCPCS Dosage 1 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71767-111-01 identifies a specific commercial package of 1 syringe, glass in 1 carton / 1 ml in 1 syringe, glass of Furoscix, a human prescription drug labeled by Scpharmaceuticals Inc., A Wholly Owned Subsidiary Of Mannkind Corporation. This product is billed per "ML" milliliter and contains an estimated amount of 1 billable units per package. This injection is formulated for subcutaneous use and contains furosemide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Scpharmaceuticals Inc., A Wholly Owned Subsidiary Of Mannkind Corporation on July 27, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a "water pill" (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

How is this Scpharmaceuticals Inc., A Wholly Owned Subsidiary Of Mannkind Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71767011101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71767-111-01
11-Digit CMS (5-4-2)
71767-0111-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.